The Aroon Indicator for ERAS entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 212 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 59 cases where ERAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ERAS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ERAS's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on ERAS as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on October 02, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 52 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +13.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 212 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.661) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RZLT advanced for three days, in 240 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on RZLT as a result. In 85 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for RZLT just turned positive on September 28, 2026. Looking at past instances where RZLT's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
The 10-day RSI Indicator for RZLT moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 28 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 52 cases where RZLT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
RZLT moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RZLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RZLT broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RZLT entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.016) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. RZLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RZLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RZLT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 47 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ERAS | RZLT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 83% | 7 days ago 90% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ERAS’s FA Score shows that 0 FA rating(s) are green while RZLT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ERAS’s TA Score shows that 4 TA indicator(s) are bullish while RZLT’s TA Score has 3 bullish TA indicator(s).
ERAS (@Biotechnology) experienced а +4.11% price change this week, while RZLT (@Biotechnology) price change was -3.42% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.81%. For the same industry, the average monthly price growth was -12.37%, and the average quarterly price growth was -18.43%.
ERAS is expected to report earnings on Nov 11, 2026.
RZLT is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPLD | 51.40 | 0.03 | +0.06% |
| JPMorgan Limited Duration Bond ETF (JPLD) | |||
| FEBM | 31.78 | -0.04 | -0.13% |
| FT Vest US Equity Max Buffer ETF-February (FEBM) | |||
| BBHL | 17.52 | -0.14 | -0.78% |
| BBH Select Large Cap ETF (BBHL) | |||
| MSD | 6.62 | -0.09 | -1.34% |
| Morgan Stanley Emerging Markets Debt Fund | |||
| SATO | 16.17 | -1.03 | -6.00% |
| Invesco Alerian Galaxy Crypto Economy ETF (SATO) | |||
A.I.dvisor indicates that over the last year, RZLT has been loosely correlated with GRI. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RZLT jumps, then GRI could also see price increases.
| Ticker / NAME | Correlation To RZLT | 1D Price Change % | ||
|---|---|---|---|---|
| RZLT | 100% | -8.24% | ||
| GRI - RZLT | 53% Loosely correlated | -8.50% | ||
| DYN - RZLT | 43% Loosely correlated | -1.70% | ||
| SYRE - RZLT | 42% Loosely correlated | -2.26% | ||
| ENVB - RZLT | 41% Loosely correlated | -4.20% | ||
| CRVS - RZLT | 41% Loosely correlated | -0.32% | ||
More | ||||